Epidemiology & Population Health

The Epidemiology and Population Health Program monitors the impact of the HIV/AIDS epidemic in British Columbia.  Research from the program focuses on how antiretroviral therapy affects the health and well being of people living with HIV.  This includes identifying risks for HIV infection, monitoring access to antiretroviral therapy, and analyzing treatment programs. The program manages a variety of research cohorts and engages in numerous international research collaborations.

Recent studies from the Epidemiology and Population Health Program have helped identify the impact of baseline CD4 cell count and viral load on disease progression, the impact of adherence on disease progression, emerging drug toxicities of antiretroviral therapy, and the effect of socioeconomic status on access to antiretroviral therapy.

If you are looking for information about the Drug Treatment Program, please click here.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search